Healthcare
908 Devices Inc.(MASS)
Live Price
Offline$8.85
+3.15% today
Window Change
+5.23%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $250.00M
- Revenue Growth
- -5.8%
- EPS Growth
- +125.5%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
908 Devices Inc. (MASS) is a Healthcare stock with a market cap of $250.00M and listed on NASDAQ. The stock last traded around $8.85 and up 5.2% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of -5.8%, EPS growth of +125.5%, a dividend yield of 0.0%. What stands out right now is revenue -5.8%, EPS +125.5%, free cash flow +20.1% with operating margin -70.1% and ROIC -22.8%. Valuation is more restrained than many high-expectation growth names at P/E 12.7 and price/sales 4.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MASS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-5.8% vs +7.6% peer median
Operating Margin
Below sector median
-70.1% vs +19.4% peer median
P/E
Below sector median
12.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -5.8% and EPS is at +125.5%, with operating margin around -70.1%.
Benchmark Edge
MASS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MASS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MASS Max Drawdown
-10.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MASS and SPY.
Company Overview
908 Devices Inc.
NASDAQ Global Market
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Leadership
- Kevin J. Knopp
- IPO Date
- Dec 18, 2020
- Employees
- 246
- Street Address
- 645 Summer Street
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 254 1500
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 12.7
- EV/EBITDA
- โ
- Price/Sales
- 4.5
- Price/Book
- 1.7
Growth
- Revenue
- -5.8%
- EPS
- +125.5%
- Free Cash Flow
- +20.1%
Profitability
- Gross Margin
- 50.6%
- Operating Margin
- -70.1%
- Net Margin
- 34.7%
- ROE
- 13.3%
- ROIC
- -22.8%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 4.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.